Li Xiang-Lin, Guan Tao, Zhao Zhi-Qiang, Liu Xiao-Lan, Wang Hui, Su Li-Ping, Wang Lie-Yang
Department of Hematology, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030000, Shanxi Province, China.
Department of Hematology, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030000, Shanxi Province, China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023;31(5):1366-1371. doi: 10.19746/j.cnki.issn.1009-2137.2023.05.018.
To investigate the clinical characteristics of diffuse large B-cell lymphoma(DLBCL) patients with bone marrow involvement and chromosome abnormalities, and further analyze the correlation between the degree of chromosome abnormality and prognosis.
The clinical data of 88 patients diagnosed with DLBCL with bone marrow involvement and complete chromosomal findings in Shanxi Province Cancer Hospital were retrospectively analyzed. The χ test was used to analyze their clinical characteristics, and the Kaplan-Meier method was used in PFS and OS, and log-rank method in comparison.
Chromosome abnormalities were detected in 31 of the 88 patients(35.2%), 15 of whom had complex karyotype(17.0%). The positive rate of , , and Ki-67≥80% was high in patients with complex karyotype, and most of them are double expressor lymphoma. Survival analysis showed that patients with complex karyotype of DLBCL had poorer PFS and OS compared to those with normal karyotype and 1-2 chromosomal abnormalities.
In DLBCL patients with bone marrow involvement and chromosome abnormalities, patients with complex karyotype have a shorter survival time.
探讨弥漫性大B细胞淋巴瘤（DLBCL）患者骨髓受累及染色体异常的临床特征，并进一步分析染色体异常程度与预后的相关性。
回顾性分析山西省肿瘤医院88例诊断为DLBCL且骨髓受累并有完整染色体检查结果的患者的临床资料。采用χ检验分析其临床特征，采用Kaplan-Meier法计算无进展生存期（PFS）和总生存期（OS），并采用对数秩检验进行比较。
88例患者中31例（35.2%）检测到染色体异常，其中15例为复杂核型（17.0%）。复杂核型患者中、、及Ki-67≥80%的阳性率较高，且大多为双表达淋巴瘤。生存分析显示，与核型正常及有1-2处染色体异常的DLBCL患者相比，复杂核型患者的PFS和OS较差。
在骨髓受累且有染色体异常的DLBCL患者中，复杂核型患者的生存时间较短。
Zotero 插件